Modality
Peptide
MOA
CAR-T CD19
Target
CD3
Pathway
Tau
Gastric Ca
Development Pipeline
Preclinical
Oct 2018
→ Jan 2025
PreclinicalCurrent
NCT06886414
320 pts·Gastric Ca
2018-10→2025-01·Terminated
320 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-271.2y agoInterim· Gastric Ca
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
Preclinical
Termina…
Catalysts
Interim
2025-01-27 · 1.2y ago
Gastric Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06886414 | Preclinical | Gastric Ca | Terminated | 320 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 |